1 / 2

The sketch illustrates the profound molecular re-

Unique Polymeric Materials by Novel Processes Joseph P. Kennedy, The University of Akron DMR-0243314.

bat
Download Presentation

The sketch illustrates the profound molecular re-

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Unique Polymeric Materials by Novel ProcessesJoseph P. Kennedy, The University of Akron DMR-0243314 Intellectual Merit: We have created and protected by US patents Amphiphilic Conetworks (APCN), i.e., two-component networks of covalently interconnected hydrophilic/hydrophobic phases of cocontinuous morphology; these unique constructs swell both in water and hydrocarbons, and respond to changes in the medium by morphological isomerization (“smart” networks). The sketch illustrates the profound molecular re- organization an APCN (comprising PEG and PDMS segments) upon contact with three media, i.e., a common, a hydrophilic, and a hydrophobic solvent. Membranes created by precision synthesis of APCNs may be used as immunoisolatory devices to correct diabetes (see next slide). For details see: G. Erdodi and J. P. Kennedy, Prog. Polym. Sci., 31 (2006) 1-18.

  2. DIACURE Inc. is the name of the company created to exploit the basic science/technology of Amphiphilic Conetworks developed by the Kennedy group at The University of Akron with NSF financial help. The aim of DIACURE is to produce a bioartificial pancreas (BAP) to correct diabetes. The BAP will consist of insulin-producing pig pancreatic cells encapsulated in a precision synthesized semipermeable amphiphilic conetwork membrane, which allows the in-diffusion of glucose and nutrient into, and out-diffusion of insulin and wastes from the device, but prevents the onslaught of the host’s (human) immune system upon the protected live cells. The BAP is in fact a glucose-sensor/insulin-delivery device that will be implanted for 6-12 months into diabetics and will produce the appropriate amount of insulin. Thus diabetics will not need to monitor their blood glucose level and self-administering of insulin becomes unnecessary.

More Related